"[14E29742586D]" . "RIV/61989592:15110/07:10213617!RIV12-MSM-15110___" . . "427801" . "Faber, Edgar" . . "Imatinib (IM), kompetitivn\u00ED inhibitor tyrozinov\u00E9 kin\u00E1zy Bcr/Abl, je registrov\u00E1n pro l\u00E9\u010Dbu nemocn\u00FDch s chronickou myeloidn\u00ED leukemi\u00ED (CML) od roku 2001. Dosavadn\u00ED zku\u0161enosti potvrzuj\u00ED jeho prioritn\u00ED postaven\u00ED v l\u00E9\u010Db\u011B CML. Na na\u0161em pracovi\u0161ti jsme k 1.4.2007 l\u00E9\u010Dili 146 nemocn\u00FDch z CML. 17 nemocn\u00FDch bylo p\u0159ed\u00E1no k dal\u0161\u00ED l\u00E9\u010Db\u011B na jin\u00E9 pracovi\u0161t\u011B, 13 bylo l\u00E9\u010Deno p\u0159ed nebo po alogenn\u00ED transplantaci krvetvorn\u00FDch bun\u011Bk, jeden odm\u00EDtl pokra\u010Dov\u00E1n\u00ED l\u00E9\u010Dby, u dvou nejsou k dispozici v\u0161echny data pro anal\u00FDzu a 11 nemocn\u00FDch je l\u00E9\u010Deno krat\u0161\u00ED dobu ne\u017E 6 m\u011Bs\u00EDc\u016F. P\u0159edm\u011Btem sd\u011Blen\u00ED jsou zku\u0161enosti s l\u00E9\u010Dbou 102 nemocn\u00FDch ? 61 mu\u017E\u016F a 41 \u017Een ve v\u011Bku 17 a\u017E 78 let (medi\u00E1n 52). Vstupn\u00ED sk\u00F3re rizika podle Sokala bylo n\u00EDzk\u00E9 u 36, intermedi\u00E1rn\u00ED u 40 a vysok\u00E9 u 24 nemocn\u00FDch. 80 nemocn\u00FDch zah\u00E1jilo l\u00E9\u010Dbu IM v chronick\u00E9 f\u00E1zi, 20 v akceleraci a 2 v blastick\u00E9m zvratu. Interval od diagn\u00F3zy do zah\u00E1jen\u00ED terapie IM se pohyboval od 1 do 135 m\u011Bs\u00EDc\u016F (medi\u00E1n 9)." . "Roho\u0148, Peter" . . . "Indr\u00E1k, Karel" . "Treatment of patients with chronic myeloid leukemia with imatinib"@en . "Mare\u0161ov\u00E1, Ivana" . "Ro\u017Emanov\u00E1, \u0160\u00E1rka" . "Holzerov\u00E1, Milena" . . "Soln\u00E1, Ren\u00E1ta" . . "SK - Slovensk\u00E1 republika" . "Imatinib (IM), a competitive inhibitor of Bcr/Abl tyrosine kinase, has been registered for the treatment of patients with chronic myeloid leukemia (CML) since 2001. Recent experience has confirmed its priority role in the treatment of CML. We have treated with imatinib (IM) 146 CML patients to 1st April 2007. 17 patients were referred to other departments, 13 were treated before or after stem cell transplantation, one refused to continue with therapy, for two patients we lacked the full data for analysis and 11 patients with CML in chronic phase has been treated for less than 6 months. We report thus the experience with therapy in 102 patients ? 61 male and 41 women 17 to 78 yer old (median 52). Sokal risk was low in 36, intermediate in 40 and high in 24 patients. 80 patients started therapy with IM in chronic phase, 20 in acceleration and 2 in blastic phase. Interval diagnosis-therapy with IM ranged from 1 to 135 months (median 9)."@en . "1335-8359" . . . "15110" . "Zapletalov\u00E1, Jana" . . . . . . "7" . "Jak postupovat p\u0159i zji\u0161t\u011Bn\u00ED rezistence na imatinib - zku\u0161enosti z Olomouce"@cs . "11"^^ . . . "Jak postupovat p\u0159i zji\u0161t\u011Bn\u00ED rezistence na imatinib - zku\u0161enosti z Olomouce" . . "Z(MSM6198959205), Z(MSM6198959223)" . . "12"^^ . "Jak postupovat p\u0159i zji\u0161t\u011Bn\u00ED rezistence na imatinib - zku\u0161enosti z Olomouce" . "2"^^ . "Jaro\u0161ov\u00E1, Marie" . "chronick\u00E1 myeloidn\u00ED leuk\u00E9mie; imatinib"@en . "Treatment of patients with chronic myeloid leukemia with imatinib"@en . "S1" . . . "Skoumalov\u00E1, Ivana" . . . . "RIV/61989592:15110/07:10213617" . . "Jak postupovat p\u0159i zji\u0161t\u011Bn\u00ED rezistence na imatinib - zku\u0161enosti z Olomouce"@cs . "Veselovsk\u00E1, Jitka" . "Imatinib (IM), kompetitivn\u00ED inhibitor tyrozinov\u00E9 kin\u00E1zy Bcr/Abl, je registrov\u00E1n pro l\u00E9\u010Dbu nemocn\u00FDch s chronickou myeloidn\u00ED leukemi\u00ED (CML) od roku 2001. Dosavadn\u00ED zku\u0161enosti potvrzuj\u00ED jeho prioritn\u00ED postaven\u00ED v l\u00E9\u010Db\u011B CML. Na na\u0161em pracovi\u0161ti jsme k 1.4.2007 l\u00E9\u010Dili 146 nemocn\u00FDch z CML. 17 nemocn\u00FDch bylo p\u0159ed\u00E1no k dal\u0161\u00ED l\u00E9\u010Db\u011B na jin\u00E9 pracovi\u0161t\u011B, 13 bylo l\u00E9\u010Deno p\u0159ed nebo po alogenn\u00ED transplantaci krvetvorn\u00FDch bun\u011Bk, jeden odm\u00EDtl pokra\u010Dov\u00E1n\u00ED l\u00E9\u010Dby, u dvou nejsou k dispozici v\u0161echny data pro anal\u00FDzu a 11 nemocn\u00FDch je l\u00E9\u010Deno krat\u0161\u00ED dobu ne\u017E 6 m\u011Bs\u00EDc\u016F. P\u0159edm\u011Btem sd\u011Blen\u00ED jsou zku\u0161enosti s l\u00E9\u010Dbou 102 nemocn\u00FDch ? 61 mu\u017E\u016F a 41 \u017Een ve v\u011Bku 17 a\u017E 78 let (medi\u00E1n 52). Vstupn\u00ED sk\u00F3re rizika podle Sokala bylo n\u00EDzk\u00E9 u 36, intermedi\u00E1rn\u00ED u 40 a vysok\u00E9 u 24 nemocn\u00FDch. 80 nemocn\u00FDch zah\u00E1jilo l\u00E9\u010Dbu IM v chronick\u00E9 f\u00E1zi, 20 v akceleraci a 2 v blastick\u00E9m zvratu. Interval od diagn\u00F3zy do zah\u00E1jen\u00ED terapie IM se pohyboval od 1 do 135 m\u011Bs\u00EDc\u016F (medi\u00E1n 9)."@cs . "Divok\u00FD, Vladim\u00EDr" . . "Intern\u00E1 medic\u00EDna" . .